[News] San Antonio Breast Cancer Symposium 2017

Debu Tripathy (University of Texas MD Anderson Cancer Center, Houston, TX, USA) and colleagues presented an interim analysis of the randomised, phase 3, MONALEESA-2 trial, the first trial investigating the addition of cyclin D1/CDK4/6 inhibitor ribociclib to standard hormone therapy in women with premenopausal or perimenopausal, hormone receptor –positive (HR-positive), HER2-negative advanced breast cancer. 672 patients were randomly assigned (1:1) to ribociclib (600 mg per day, 3-weeks on, 1-week off; n=335) or placebo (n=337) in combination with tamoxifen (20 mg per day) or a nonsteroidal aromatase inhibitors (letrozole [2·5 mg per day ] or anastrozole [1 mg per day]) plus goserelin (3·6 mg every 28 days).
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: News Source Type: research